Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008963 | 0.71 | — | — | |
| SCHEMBL3819753 | 0.71 | — | — | |
| SCHEMBL30478908 | 0.71 | CA12 (0.36) | SLC9A1CA12CA9MEN1GAA | |
| SCHEMBL5757118 | 0.71 | ALDH1A1 (0.52) | PARP1MEN1GAAKMT2ATYMS | |
| SCHEMBL276979 | 0.71 | MEN1 (0.33) | MEN1KMT2APTPN1 | |
| SCHEMBL23468415 | 0.71 | NOS1 (0.38) | NOS1DYRK1ATYMS | |
| Hydrochloric Acid SCHEMBL27934211 | 0.70 | CYP1A2 (0.50) | CA12CA9PARP1MEN1KMT2A | |
| Bromide SCHEMBL8507879 | 0.70 | CYP1A2 (0.50) | CA12CA9PARP1MEN1KMT2A | |
| SCHEMBL69629 | 0.69 | ALDH1A1 (0.53) | BACE1CA9PARP1 | |
| SCHEMBL29405063 | 0.69 | ALDH1A1 (0.53) | BACE1CA9PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676785-B2 | HCV protease inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2017-06-13 | — | — | US | disclosed |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-05-18 | — | — | US | disclosed |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140323465-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2014-10-30 | — | — | US | disclosed |
| US-8778877-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8741837-B2 | HCV protease inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130017991-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8293705-B2 | HCV protease inhibitors and uses thereof | AVILA THERAPEUTICS, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2011002808-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| EP-2237666-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-10-13 | — | — | EP | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009082701-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| US-6265408-B1 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANT | SMITHKLINE BEECHAM PLC (GB) | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323465-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | AHR 2697/4885SLC9A1 4549/4885NOS1 3304/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | AHR 2697/4885SLC9A1 4549/4885NOS1 3304/4885 |
| US-20170137463-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | AHR 2697/4885SLC9A1 4549/4885NOS1 3304/4885 |
| US-20150031106-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | AHR 2697/4885SLC9A1 4549/4885NOS1 3304/4885 |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | AHR 2697/4885SLC9A1 4549/4885NOS1 3304/4885 |
| US-20130017991-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | AHR 2697/4885SLC9A1 4549/4885NOS1 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.